Last reviewed · How we verify
Pneumo 23™
At a glance
| Generic name | Pneumo 23™ |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older (PHASE3)
- Evaluation of Pneumococcal Vaccine Formulations in Elderly (PHASE1)
- Evaluation of Pneumococcal Vaccine Formulations in Young Adults (PHASE1)
- Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumo 23™ CI brief — competitive landscape report
- Pneumo 23™ updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI